Skip to content

Misoprostol With or Without Letrozole in Treatment of Missed Miscarriage

Study at Zagazig General Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04593108
Enrollment
320
Registered
2020-10-19
Start date
2019-01-15
Completion date
2020-11-15
Last updated
2020-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Missed Abortion

Brief summary

Aim of study Compare the success rate of misoprostol with versus without letrozole as a pretreatment for medical termination of pregnancy during the first trimester. Hypothesis: Letrozole value as a pre-treatment medication for misoprostol in induction of abortion during the first trimester. Research question: Will letrozole- misoprostol protocol give better results than misoprostol- alone protocol in induction of abortion during the first trimester?

Detailed description

Aim of the Work Compare the success rate of misoprostol with versus without letrozole as a pretreatment for medical termination of pregnancy during the first trimester. Hypothesis: Letrozole value as a pre-treatment medication for misoprostol in induction of abortion during the first trimester. Research question: Will letrozole- misoprostol protocol give better results than misoprostol- alone protocol in induction of abortion during the first trimester? Primary outcome: Complete abortion (complete expulsion of products of conception with no need for curettage) within one week from the first dose of misoprostol. Secondary outcome: • Curettage (surgical evacuation of the products of conception) * Incomplete abortion (retained products of conception). * Considerable bleeding that necessitates immediate evacuation.

Interventions

DEVICELetrozole misoprostol

Letrozole give pretreatment of abortion by misoprostol

DRUGMisoprostol, placebo

Give placebo pretreatment of abortion by misoprostol

Sponsors

Benha University
CollaboratorOTHER
Dr.Dalia Mohammed Al Sayed Zaki
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Woman age more than 18 years old (age of legal consent). * BMI ranges between 25 kg/m2 and 35 kg/m2. * Gestational age of 63 days' gestation (or less). * Missed abortion. * Hemoglobin leve

Exclusion criteria

* Woman age less than 18 years old. * BMI less than 25 kg/m2 or more than 35 kg/m2. * Gestational age more than 63 days' gestation. * Molar pregnancy. * Hemoglobin level less than 10 gm/dL. * Fibroid uterus. * Uterus with congenital anomalies. * Previous attempts for induction of abortion in the current pregnancy. * Coagulation defect i.e. coagulopathy. * Contraindication for induction of abortion e.g. heart failure. * Allergy to misoprostol or letrozole.

Design outcomes

Primary

MeasureTime frameDescription
Complete abortion1weekComplete abortion (complete expulsion of products of conception with no need for curettage) within one week from the first dose of misoprostol.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026